GSC
HRTX icon

Ground Swell Capital’s Heron Therapeutics HRTX Stock Holding History

Ground Swell Capital’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$5K Buy
+652
New +$6.07K 0.01% 1447

Other funds holding HRTX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Ground Swell Capital's HRTX Position: Q3 2014 in Review

Ground Swell Capital opened a new position in Heron Therapeutics (HRTX) in Q3 2014: 652 shares worth $5K. The stake represents 0.01% of the portfolio and ranks #1447 among its holdings.

59 funds tracked by Wall St. Rank hold HRTX as of Q3 2014.

  • Ground Swell Capital held 652 shares of Heron Therapeutics worth $5K as of Q3 2014.
  • Heron Therapeutics was a new Ground Swell Capital position in Q3 2014.
  • Heron Therapeutics made up 0.01% of Ground Swell Capital's portfolio in Q3 2014, its #1447 holding.
  • 59 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2014.

Based on Ground Swell Capital's 13F filing for Q3 2014, filed 6 Nov 2014.